Jason Sakamoto Ph.D.

Jason Sakamoto, Ph.D. 

Jason Sakamoto, Ph.D. Assistant Member Interim Co-Chair The Department of Nanomedicine The Methodist Hospital Research Institute Center Manager, Center for Transport Oncophysics NCI Physical Science and Oncology Center Center Manager, Texas Center for Cancer Nanomedicine NCI Center of Cancer Nanotechnology Excellence Chief Operating Officer Alliance for NanoHealth E-mail: jhsakamoto@tmhs.org Office: 713-441-7350 Cell: 281-726-0955

Education

Biography

Dr. Sakamoto is a faculty member of The Methodist Hospital Research Institute in Houston, Texas, where he leads research efforts developing novel nano-therapeutic drug delivery systems and nano-based proteomics technologies. He is a co-inventor of the multi-stage nanoporous silicon nanovector delivery system technology that is currently being commercialized by Leonardo BioSystems. Dr. Sakamoto serves as an Interim Co-Chair of the Department of Nanomedicine at TMHRI. He also serves as the Chief Operating Officer of the Alliance for NanoHealth. The Alliance is a consortium of eight institutions of the Greater Houston Texas Region. The mission of the Alliance is to collectively bridge the disciplines to develop nanotechnology-based solutions to unresolved problems in medicine and to facilitate the clinical translation of these new technologies through commercialization. Dr. Sakamoto also serves as a consultant for the Arrowhead Research Corporation, assigned to the technology and business development of Leonardo Biosystems.

Prior to his services in Houston, Dr. Sakamoto completed his undergraduate degree in Material Science Engineering from the University of California at Berkeley under the mentorship of Dr. Mauro Ferrari. After graduating, he entered the medical device industry and was employed as coronary and peripheral stent manufacturing and process engineer at the Guidant Corporation in Santa Clara, California. During these years at Guidant, he played a significant role in the regulatory approval process of three medical devices and was responsible for the GMP production of coronary/peripheral stents for over a year. After Guidant, he rejoined Dr. Ferrari's research team and received his doctorate in Biomedical Engineering from The Ohio State University. Upon completion of his Ph.D., Dr. Sakamoto remained as a post-doctoral researcher in Dr. Ferrari's nanomedicine research group, while working as a business development consultant for several biotech start-ups. He has written several publications on nanomedicine including peer-reviewed journal articles and book chapters, and is an inventor on two pending U.S. patent applications.

Description of Research

Dr. Sakamoto leads the Nanochip Proteomics program in the Department of Nanomedicine. This technology analyzes proteomic signatures of the low molecular weight proteome and peptidome found in bodily fluids to monitor disease progression and patient response to therapy. He also develops novel nanovector therapeutics for cancer and other clinical applications.

Major Areas of Research

Cancer, nanotechnology, personalized medicine, proteomics, multistage

Recent Publications

Hu Y, Peng Y, Lin K, Shen H, Brousseau L, Sun T, Sakamoto J, Ferrari M. Surface Engineering on Mesoporous Silica Chips for Enriching Low Molecular Weight Phosphorylated Proteins. Nanoscale. (2010) Dec 7. [Epub ahead of print] PMID: 21135976

Godin B, Sakamoto J, Serda R, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseases. Trends Pharmacol Sci (TiPS). 31(5):199-205 (2010)

Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A, Ziemys A, Bouamrani A, Hu T, Ranganathan SI, De Rosa E, Martinez JO, Smid CA, Buchanan RM, Lee SY, Srinivasan S, Landry M, Meyn A, Tasciotti E, Liu X, Decuzzi P, Ferrari M. Enabling individualized therapy through nanotechnology. Pharmacological Research. 62(2):57-89 (2010)

Tascotti E, Sakamoto JH, Ferrari M. Conference scene: nanotechnology and medicine: the next big thing is really small. Nanomedicine. 4(6):619-21 (2009)

Godin B, Serda RE, Sakamoto JH, Decuzzi P, Ferrari M. Nanoparticles for Cancer Detection and Therapy. In : Vogel V. (Ed.) Nanotechnology. Volume 5: Nanomedicine and Nanobiotechnology, Wiley-VCH Verlag GmbH & Co. KGaA Weinheirn, 2009, pp. 51-88

Tanaka T, Decuzzi P, Cristofanilli M, Sakamoto JH, Tasciotti E, Robertson FM, Ferrari M. Nanotechnology for breast cancer therapy. Biomed Microdevices. 11(1):49-63 (2008)

Sanhai WR, Sakamoto JH, Canady R., Ferrari M. Seven challenges for nanomedicine. Nature Nanotechnology. 3:242-244 (2008)

Pope-Harman A, Cheng MM, Robertson F, Sakamoto JH, Ferrari M. Biomedical nanotechnology for cancer. Med Clin North Am. 91:899-927 (2007).

Sakamoto JH, Annapragada A, Decuzzi P, Ferrari M. Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv. 4:359-69 (2007)

Sakamoto JH, Ferrari M. "Introduction" in SAGE Sourcebook of Modern Biomedical Devices (ed. Millennium Research Group, series ed. Alpern, T.) (SAGE Publications, Los Angeles, 2007) xix-xxxiii

Jason Sakamoto, Paolo Decuzzi, Francesco Gentile, Stanislav I Rokhlin, Lugen Wang, Bin Xie, and Mauro Ferrari.  Nanomechanics and Tissue Pathology in Biological and Biomedical Nanotechnology (eds. Lee, A. P. & Lee, L. J., series ed. Ferrari, M.) (Springer, New York, 2006) 461-503

Sakamoto JH, Smith BR, Xie B, Rokhlin SI, Lee SC, Ferrari M. The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol Cancer Res Treat. 4:627-36 (2005)

Links

The Alliance for NanoHealth

Center for Transport Oncophysics